Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prg25-03
- Development stage
- Preclinical
- Lead developer
- Tessellate BIO
- Modality
- Small Molecules
01
Overview
Prg25-03 is a preclinical-stage therapeutic program developed by Tessellate Bio, focusing on synthetic lethality in non-homologous recombination deficiency (non-HRD) cancers. The drug targets S-phase kinase-associated protein 2 (SKP2) to exploit vulnerabilities created by the loss-of-function of specific tumor suppressors. This precision medicine approach utilizes Next Generation Sequencing (NGS) as a companion diagnostic for patient selection, aiming to treat cancers that do not typically respond to HRD-targeted therapies. The program is part of a broader pipeline focused on DNA Damage Response and Tumor Suppressor Loss-of-Function in oncology.
- Other names
- Tumor suppressor LoF program
02
Targets
SKP2
Beyond the preview
Go deeper on Prg25-03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prg25-03.